山东大学耳鼻喉眼学报 ›› 2016, Vol. 30 ›› Issue (4): 105-108.doi: 10.6040/j.issn.1673-3770.0.2016.002

• 论著 • 上一篇    下一篇

玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察

严晓腾,冯军,康欣乐   

  1. 徐州医学院附属淮安医院眼科, 江苏 淮安 223002
  • 收稿日期:2016-01-01 出版日期:2016-08-16 发布日期:2016-08-16
  • 作者简介:严晓腾. E-mail:caoben0429@sina.com

Intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion.

YAN Xiaoteng, FENG Jun, KANG Xinle   

  1. Deparment of ophthalmology, Affiliated Huaian Hospital of Xuzhou Medical College, Huaian 223002, Jiangsu, China
  • Received:2016-01-01 Online:2016-08-16 Published:2016-08-16

HTML

PDF (PC)

606

摘要： 目的 探讨玻璃体腔注射康柏西普治疗视网膜静脉阻塞(retinal vein occlusion, RVO)继发黄斑水肿(macular edema, ME)的有效性。 方法 采用前瞻性连续性非对照的临床病例分析。选择2014年9月至2015年2月就诊的RVO继发ME 30例30眼,其中视网膜中央静脉阻塞(central retinal vein occlusion, CRVO)继发的ME 9例9眼,视网膜分支静脉阻塞(branch retinal vein occlusion, BRVO)继发的ME 21例21眼。玻璃体腔注射康柏西普治疗3次,随访6个月,观察最佳矫正视力(best corrected visual acuity, BCVA)、黄斑中心凹视网膜厚度(central macular thickness, CMT)。 结果 BRVO患眼治疗前及治疗后6个月BCVA分别为(0.77±0.24)logMAR、(0.27±0.19)logMAR,CMT分别为(596.8±139.6)μm、(272.6±29.2)μm,差异具有显著统计学意义(t=4.483, P<0.05; t=7.189, P<0.05);CRVO患眼治疗前及治疗后6个月BCVA分别为(0.87±0.55)logMAR、(0.43±0.2)logMAR,CMT分别为(647.3±163.6)μm、(393.1±121.5)μm,差异具有显著统计学意义(t=2.288, P<0.05; t=7.189, P<0.05)。 结论 玻璃体腔注射康柏西普是一种治疗RVO继发ME的有效方式。

关键词: 视网膜静脉阻塞, 黄斑水肿, 康柏西普, 玻璃体腔注射

Abstract: Objective To explore the effects of intravitreal injection of conbercept for macular edema(ME)secondary to retinal vein occlusion(RVO). Methods A prospective, continuity and uncontrolled clinical case analysis was used. Thirty cases(30 eyes)with ME secondary to RVO in our hospital from September 2014 to February 2015 were selected, in which 9 cases(9 eyes)were central retinal vein occlusion(CRVO)and 21 cases(21 eyes)were branch retinal vein occlusion(BRVO). All cases were treated with intravitreal injection of conbercept for 3 times and followed up for 6 months. Best corrected visual acuity(BCVA)and central macular thickness(CMT)were observed. Results In patients with BRVO, mean BCVA before treatment and 6 months after treatment were(0.77±0.24)logMAR,(0.27±0.19)logMAR, and CMT were(596.8±139.6)μm,(272.6±29.2)μm, respectively, the difference has statistical significance(t=4.483, P<0.05; t=7.189, P<0.05). In patients with CRVO, mean BCVA before treatment and 6 months after treatment were(0.87±0.55)logMAR,(0.43±0.2)logMAR, and CMT were(647.3±163.6)μm,(393.1±121.5)μm, respectively, the difference has statistical significance(t=2.288, P<0.05; t=7.189, P<0.05). Conclusion Intravitreal injections of conbercept is effective for ME secondary to RVO.

Key words: Intravitreal injection, Retinal vein occlusion, Macular edema, Conbercept

中图分类号: 

  • R774.5
[1] Klein R, Klein B E, Moss S E, et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study[J]. Trans Am Ophthalmol Soc, 2000, 98:133-141.
[2] Finkelstein D. Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion[J]. Arch Ophthalmol, 1992, 110(10):1427-1434.
[3] 乔森(著), 陈有信(译). 视网膜血管性疾病[M]. 北京:科学出版社, 2011: 423.
[4] Klein M L, Finkelstein D. Macular grid photocoagulation for macular edema in central retinal vein occlusion[J]. Arch Ophthalmol, 1989, 107(9):1297-1302.
[5] Parodi M B, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion[J]. Graefes Archive for Clinical and Experimental Ophthalmology, 1999(12):1024-1027.
[6] Jonas J B, Kreissig I, Kamppeter B, et al. Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases[J]. Ophthalmologe, 2004, 101(2):113-120.
[7] Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion[J]. Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie, 2006, 244(3):309-315.
[8] Brown D M, Campochiaro P A, Bhisitkul R B, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study[J]. Ophthalmology, 2011, 118(8):1594-1602.
[9] Campochiaro P A, Brown D M, Awh C C, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study[J]. Ophthalmology, 2011, 118(10):2041-2049.
[1] 靳琳,潘庆敏,胡磊. 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 96-98.
[2] 严槟,尹小芳,叶祖科,卢彦,洪剑威. 玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 110-113.
[3] 韩克阳,王淑雅,焦芮,于贝贝综述, 赵博军审校. 视网膜静脉阻塞的发病机制及黄斑水肿的抗-VEGF治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 123-126.
[4] 邢凯,亢泽峰. 玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 80-82.
[5] 严晓腾, 冯军, 康欣乐. 曲安奈德玻璃体腔注射联合格栅样光凝治疗囊样黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 60-63.
[6] 孙洪义, 张晗. 2型糖尿病患者超声乳化白内障摘除并人工晶体植入手术后黄斑区光学相干断层扫描改变[J]. 山东大学耳鼻喉眼学报, 2014, 28(6): 72-76.
[7] 严晓腾,康建芳,冯军. 早期激光联合曲安奈德治疗视网膜颞上支静脉阻塞继发黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 75-76.
[8] 谢丽综述，魏伟审校. 糖尿病性黄斑水肿的治疗进展[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 81-85.
[9] 王永波，石安娜，石浔，金昱，刘维锋. 视网膜静脉阻塞患者光感受器细胞层与最佳视力之间的关系[J]. 山东大学耳鼻喉眼学报, 2013, 27(1): 78-80.
[10] 李晋齐1，王静波2，赵靖1. 中药结合激光治疗RVO的临床观察[J]. 山东大学耳鼻喉眼学报, 2010, 24(5): 62-.
[11] 王琳，关娟，周历，盛豫，司艳芳，赵慧英，赵娟. 高脂血症与视网膜静脉阻塞发病的相关性研究[J]. 山东大学耳鼻喉眼学报, 2010, 24(01): 44-46.
[12] 杨丽敏. 曲安奈德离子导入治疗视网膜黄斑水肿的临床观察[J]. 山东大学耳鼻喉眼学报, 2009, 23(5): 71-72.
[13] 盛艳娟 王玉 舒相汶. 曲安奈德玻璃体腔注射联合激光光凝治疗糖尿病性黄斑水肿24例[J]. 山东大学耳鼻喉眼学报, 2008, 22(6): 541-543.
[14] 吴昌龙 综述,王 玉 审校 .

糖尿病黄斑水肿的治疗

[J]. 山东大学耳鼻喉眼学报, 2008, 22(4): 369-372 .
[15] 卢爱东,刘晓玲,高 洁,陈 芳,梁仲琪 . 曲安奈德联合微脉冲激光治疗糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2008, 22(4): 366-368 .
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发